CU Cancer Center's Innovative Approaches Lead to Higher Survival Rates
核心洞察
The CU Cancer Center (搜索) demonstrates higher five-year survival rates, particularly in cancers of the esophagus, liver, pancreas, lungs, and stomach.
Clinical trials at the CU Cancer Center (搜索) provide patients access to advanced treatments, significantly improving outcomes, especially in lung cancer (搜索).
Innovative treatments like the hepatic arterial infusion pump (HAI) offer new hope for patients with advanced cancers, converting them to surgical candidates.
The CU Cancer Center (搜索) is demonstrating improved five-year survival rates, particularly for cancers of the esophagus, liver, pancreas, lungs, and stomach, according to data from UCHealth. This success is attributed to access to advanced treatments through clinical trials and personalized care approaches.
Factors Contributing to Improved Survival
"Seeing that our survival rates are higher is certainly a point of pride for the CU Cancer Center (搜索)," said Dr. Wells Messersmith, associate director of clinical services. He emphasized that multiple factors contribute to these improved rates, including the comprehensive care provided at the center.
Dr. D. Ross Camidge highlighted the importance of clinical trials, stating, "We’re trying to get access to tomorrow’s treatments today." He noted that a significant percentage of their lung cancer (搜索) patients are enrolled in clinical trials, far exceeding the national average.
Innovative Treatments and Personalized Approaches
Glen Miller, a colorectal cancer (搜索) patient with liver metastasis, benefited from a hepatic arterial infusion pump (HAI), which delivers high-dose chemotherapy directly to the liver. According to Dr. Reed Weiss, this approach aims to shrink tumors and control the disease, potentially making patients eligible for surgery.
Miller's journey began with a grim prognosis, but after seeking a second opinion at the CU Cancer Center (搜索), he received a treatment plan involving chemotherapy, surgeries, and the HAI pump. He has now been cancer-free for nearly three years.
Clinical Trials: A Lifeline for Patients
Charlotte Butler, diagnosed with endometrial cancer (搜索), participated in a clinical trial led by Dr. Bradley Corr, focusing on preventing recurrence using the oral drug rucaparib, a PARP inhibitor. The trial demonstrated that rucaparib extended progression-free survival by an average of 19 months compared to surveillance alone.
Butler's participation in the trial proved beneficial, as she remained cancer-free throughout the study. Dr. Corr believes she experienced significant benefit from the therapy.
The Importance of Second Opinions
Jason Patton's story underscores the importance of seeking a second opinion. Initially misdiagnosed with pancreatitis, a subsequent evaluation revealed ampullary cancer (搜索). Dr. Marco Del Chiaro performed a Whipple procedure, followed by chemotherapy, leading to Patton's successful recovery.
Dr. Del Chiaro emphasized that early detection and timely treatment are crucial for positive outcomes. Patton's proactive approach and positive attitude played a significant role in his successful treatment and recovery.